ArticleActa pharmaceutica Sinica. B2026

Rifamycin O as a novel CRBN ligand for targeted degradation of IKZF1/3 proteins in hematopoietic malignancies.

Liang Liao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.